ライフサイエンスコーパス: immunoglobulin G

1 pecific adsorption of albumin, lysozyme, and immunoglobulin G.

2 serum glycoproteins, alpha-1-antitrypsin and immunoglobulin G.

3 also enrich glycans from ovalbumin and human immunoglobulin G.

4 ction 10ng/ml) and selectivity towards human immunoglobulin G.

5 tion ~10ng/ml) and selectivity towards human immunoglobulin G.

6 54 having an inhibitor titer of 34 000 BU/mg immunoglobulin G.

7 Specific immunoglobulin G(4) to both allergens increased signific

8 s of immunoglobulin M, immunoglobulin A, and immunoglobulin G against C. difficile toxin A were depre

9 te-mefloquine (ASMQ) were screened for total immunoglobulin G against preerythrocytic and erythrocyti

10 There was an unexpected persistence of immunoglobulin G almost until weaning, potentially indic

11 Here, three model proteins, immunoglobulin G, alpha-chymotrypsinogen A, and lysozyme

12 However, they completely failed to produce immunoglobulin G, although they were not impaired in imm

13 determined the prevalence of anti-SARS-CoV-2 immunoglobulin G among blood donors in Kenya in April-Ju

14 The age-weighted prevalence of dengue immunoglobulin G among residents was 49.8% (95% confiden

15 sia, several vaccine/pathogen-specific serum immunoglobulin G and A (IgG and IgA) titers remain relat

16 n inhibition [HAI], microneutralization, and immunoglobulin G and immunoglobulin A (both serum and mu

17 ndrome coronavirus 2 (SARS-CoV-2), including immunoglobulin G and immunoglobulin A antibodies.

18 Peripheral anti-lipopolysaccharide immunoglobulin G and immunoglobulin A responses were sig

19 nasopharyngeal colonization and induction of immunoglobulin G and immunoglobulin A to all antigens te

20 yme-linked immunosorbent assay for anti-HCMV immunoglobulin G and immunoglobulin M and for cIL-10 and

21 Multiplexed assay of human immunoglobulin G and M (IgG and IgM) antibodies with EDP

22 ) mice had reduced levels of CD4(+) T cells, immunoglobulin G and M levels, and Th1 and Th2 cytokines

23 elicited as robust and significant specific immunoglobulin G and neutralizing antibodies as those in

24 ks demonstrated readily detectable levels of immunoglobulin G and/or immunoglobulin M in human plasma

25 um is needed to complement tests that detect immunoglobulins G and M.

26 NMOSD patients were positive for aquaporin-4-immunoglobulin G, and all sarcoidosis cases were patholo

27 eradish peroxidase (HRP), bovine hemoglobin, immunoglobulin G, and glucose oxidase (GOx)), which have

28 glucose, ascorbic acid human serum protein, immunoglobulin G, and immunoglobulin M), and demonstrate

29 nd total protein, albumin, immunoglobulin A, immunoglobulin G, and immunoglobulin M).

30 lyte binding interactions between anti-human immunoglobulin G (anti-hIgG) and human immunoglobulin G

31 Polyclonal anti-immunoglobulin G (anti-IgG) secondary antibodies are ess

32 e assessments and had anti-Toxoplasma gondii immunoglobulin G (anti-Toxo IgG) measured by qualitative

33 nes, correlated directly with B. burgdorferi immunoglobulin G antibodies (P </= .02), suggesting a be

34 lack of BB0405-specific immunoglobulin M or immunoglobulin G antibodies during natural infection, mi

35 Anti-F immunoglobulin G antibodies rose 6.5-15.6-fold, with sig

36 our studies on posttransplant production of immunoglobulin G antibodies targeting cell surface antig

37 nsitive and specific Luminex-based assay for immunoglobulin G antibodies to 4 Ebola virus species.

38 ax transmission, we measured total levels of immunoglobulin G antibodies to 5 PvDBP variants and used

39 mmunosorbent assay kits for immunoglobulin M/immunoglobulin G antibodies to herpes simplex virus 1 an

40 on and 1 week postvaccination was tested for immunoglobulin G antibodies to P. falciparum circumsporo

41 ntrations and neutralizing activity of serum immunoglobulin G antibodies to the RSV prefusion (pre-F)

42 All serum samples were tested for anti-ZIKV immunoglobulin G antibodies using a recombinant antigen-

43 itive in 33.6%, whereas immunoglobulin M and immunoglobulin G antibodies were positive in 15.7% cases

44 complementarity determining regions of human Immunoglobulin G antibodies with target affinities that

45 latelets, which is their unique receptor for immunoglobulin G antibodies, positions them to ideally r

46 itis C therapy in patients carrying anti-HEV immunoglobulin G antibodies, raising 2 major questions:

47 High-titer BBI39 immunoglobulin G antibodies, which have borreliacidal pr

48 thogenesis that features platelet-activating immunoglobulin G antibodies.

49 by measuring serotype-specific pneumococcal immunoglobulin G antibody concentrations at baseline and

50 synthesis of borrelial immunoglobulin M and immunoglobulin G antibody in 100%, 81.1%, 63%, and 88.7%

51 Higher immunoglobulin G antibody levels among those seropositiv

52 defined a priori as those with subprotective immunoglobulin G antibody levels to >/=66% of vaccines t

53 ot succumb to infection, the detection of an immunoglobulin G antibody response along with observed c

54 mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral sp

55 No association between total immunoglobulin G antibody responses to any PvDBP variant

56 On day 29, 92.9% of vaccinees had an anti-F immunoglobulin G antibody seroresponse.

57 Eight patients with endocarditis had phase I immunoglobulin G antibody titers >800 but did not meet t

58 ing to the presence of highly elevated serum immunoglobulin G antibody titers with a high avidity ind

59 with a faster decline of maternally derived immunoglobulin G antibody to both the EBV viral capsid a

60 r serological testing for anti-measles virus immunoglobulin G antibody.

61 that a 6 kDa affibody protein and a 150 kDa immunoglobulin-G antibody could be modified without dimi

62 e also studied the presence of EBOV-specific immunoglobulin G, antinuclear antibodies, anti-cyclic ci

63 No differences in EBOV-specific immunoglobulin G, antinuclear antibody, or anti-cyclic c

64 ell-based assays for MOG-IgG and aquaporin-4 immunoglobulin G (AQP4-IgG).

65 bivalent antigen-binding fragment regions of immunoglobulin G are sufficient to trigger adverse event

66 etitive Luminex immunoassay (cLIA) and total immunoglobulin G assay.

67 Serum Borrelia immunoglobulin M and immunoglobulin G at the time of positive Borrelia intrat

68 Only immunoglobulin G avidity index was higher in nontransmit

69 globulin M-positive and low or moderate HCMV immunoglobulin G avidity.

70 ed cases' sera for measles immunoglobulin M, immunoglobulin G, avidity, and plaque reduction neutrali

71 s (n = 5,369) were analyzed for anti-PEG-ASP immunoglobulin G by enzyme-linked immunosorbent assay.

72 We observed a transient and noninhibitory immunoglobulin G class 2 response against cFVII only in

73 possible to detect single binding events of immunoglobulin-G-coated polystyrene beads, which are hel

74 actose-alpha1,3-galactose, immunoglobulin M, immunoglobulin G, complement, fibrin, tissue factor, fib

75 The primary endpoint was serotype-specific immunoglobulin G concentrations values (geometric mean c

76 a) generated upon digestion with recombinant immunoglobulin G-degrading enzyme of Streptococcus pyoge

77 I-AM, with high immunoproteasome expression, immunoglobulin G deposition, interleukin-17 production i

78 the sandwich immunoassay developed for mouse immunoglobulin G, detection limits of 1.5 ng/mL and >10

79 Immunoglobulin G developed rapidly and was sustained at

80 ) by a multiplexed virus-like particle-based immunoglobulin G direct enzyme-linked immunosorbent assa

81 oconversion, defined as a 4-fold increase in immunoglobulin G directed against Cryptosporidium gp15 a

82 eater fecal immunoglobulin A, but not plasma immunoglobulin G, directed against the Cryptosporidium s

83 infection in vitro that was mediated through immunoglobulin G engagement of Fcgamma receptors.

84 for presence of ZIKV antibodies using a ZIKV immunoglobulin G enzyme-linked immunosorbent assay and a

85 cture in favor, serotonin release assay, and immunoglobulin G enzyme-linked immunosorbent assay posit

86 spective study patients were tested with the immunoglobulin G enzyme-linked immunosorbent assay, the

87 Polymorphisms in the immunoglobulin G Fc receptor II (FcGR) and tumor necrosi

88 Receptors recognizing the Fc part of immunoglobulin G (FcgammaRs) are key determinants in ant

89 Therefore, immunoglobulin G from 18 acute iTTP patients was purifie

90 Among 34 patients (91.9%) with monoclonal immunoglobulin G gammopathy, 20 (58.8%) had kappa light

91 achieving postvaccination serotype-specific immunoglobulin G >=0.35 ug/mL and >=4-fold rise, compare

92 blood eosinophils seeded on heat-aggregated immunoglobulin G (HA-IgG).

93 Parkinson disease in relation to leukocytes, immunoglobulin G, haptoglobin, and uric acid.

94 94 anti-SARS-CoV-2 antibodies and found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3

95 A pool of intact ovine immunoglobulin G, herein termed EBOTAb, was prepared fro

96 roteins (human serum albumin (HSA) and human immunoglobulin G (HIgG)) and achieved an ultralow detect

97 human immunoglobulin G (anti-hIgG) and human immunoglobulin G (hIgG).

98 ascribed to maternally-derived anti-parasite immunoglobulin G; however, the targets of these protecti

99 T-cell count >500/muL (median, 966/muL) and immunoglobulin G (IgG) >500 mg/dL (median, 727 mg/dL).

100 n the presence of reactive, non-neutralizing immunoglobulin G (IgG) (RNNIg) is the greatest risk fact

101 ng curves for two human antibody subclasses, immunoglobulin G (IgG) 1 and IgG4, on five different x-r

102 Plasma immunoglobulin G (IgG) Ab levels directed against HIV-1

103 DENV-specific immunoglobulin G (IgG) and DENV-1-4 serotype-specific ne

104 arial fever and coordinated with Pf-specific immunoglobulin G (IgG) and Fc receptor activation to con

105 rum was evaluated for PcrV- and Psl-specific immunoglobulin G (IgG) and for cytotoxicity and opsonoph

106 Plasma samples were tested for H1/stalk immunoglobulin G (IgG) and hemagglutination inhibition (

107 Immunoglobulin G (IgG) and Hepatitis B surface Antigen (

108 the selective naked-eye detection of rabbit immunoglobulin G (IgG) and human-prostate-specific antig

109 4008_N1 and M1214_N1, that class-switched to immunoglobulin G (IgG) and IgA.

110 says to determine the prevalence of anti-HEV immunoglobulin G (IgG) and IgM among 10,569 French blood

111 ow immunoassay test that detected SARS-CoV-2 immunoglobulin G (IgG) and immunoglobulin M (IgM) antibo

112 We measured PS immunoglobulin G (IgG) and immunoglobulin M (IgM) antibo

113 protective role for both Chlamydia-specific immunoglobulin G (IgG) and polymorphonuclear neutrophils

114 alylated N-glycans between bovine and rabbit immunoglobulin G (IgG) and the search for serum sialylat

115 Functionality of immunoglobulin G (IgG) antibodies against 24 merozoite a

116 Immunoglobulin G (IgG) antibodies against intact merozoi

117 Immunoglobulin G (IgG) antibodies against pertussis toxi

118 om bradyzoite infection by identification of immunoglobulin G (IgG) antibodies against T. gondii embr

119 Immunoglobulin G (IgG) antibodies against the capsular p

120 Immunoglobulin G (IgG) antibodies are crucial for protec

121 During pregnancy immunoglobulin G (IgG) antibodies are transferred from m

122 Current methods for producing immunoglobulin G (IgG) antibodies in engineered cells of

123 mmunofluorescence antibody assay to identify immunoglobulin G (IgG) antibodies reactive with Ricketts

124 immunoassay (MMIA) to simultaneously detect immunoglobulin G (IgG) antibodies specific for recombina

125 The immunoglobulin G (IgG) antibodies to all 3 MMR antigens

126 Dengue immunoglobulin G (IgG) antibodies were measured at basel

127 successful induction of J8-specific systemic immunoglobulin G (IgG) antibodies when administered subc

128 Infection induced lasting EBOV-specific immunoglobulin G (IgG) antibodies, but their subclass co

129 rin-induced thrombocytopenia (HIT) is due to immunoglobulin G (IgG) antibodies, which bind platelet f

130 Manaus, 44% of the population had detectable immunoglobulin G (IgG) antibodies.

131 We developed an HCV immunoglobulin G (IgG) antibody avidity assay by modifyi

132 ntrations, cell-mediated immunity (CMI), and immunoglobulin G (IgG) antibody avidity were assessed at

133 Pre-F immunoglobulin A (IgA) and immunoglobulin G (IgG) antibody levels were measured in

134 Mumps virus-specific immunoglobulin G (IgG) antibody responses and mumps viru

135 f PCV and were assessed for antipneumococcal immunoglobulin G (IgG) antibody titers against the 7 ser

136 f PCV and were assessed for antipneumococcal immunoglobulin G (IgG) antibody titers against the seven

137 Immunoglobulin G (IgG) antibody was not required for Fcg

138 In this paper, immunoglobulin G (IgG) antibody-binding domain of protei

139 acaques were measured in a multiplex Luminex immunoglobulin G (IgG) assay and opsonophagocytic activi

140 e 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against

141 Human immunoglobulin G (IgG) autoantibodies to glycine recepto

142 Immunoglobulin G (IgG) avidity and plaque reduction neut

143 However, immunoglobulin G (IgG) can also stimulate antiviral resp

144 They were predominantly of the immunoglobulin G (IgG) class and targeted the S2 subunit

145 tivation instigates MZ B-cell proliferation, immunoglobulin G (IgG) class switching, and plasmablast

146 he measurement of immunoglobulin M (IgM) and immunoglobulin G (IgG) classes of antibodies separately.

147 We assessed anti-MenA immunoglobulin G (IgG) concentrations (n = 200) and, usi

148 c opsonophagocytic activity (OPA) titers and immunoglobulin G (IgG) concentrations were determined.

149 Serotype-specific immunoglobulin G (IgG) concentrations, and pneumococcal

150 NmA strain 3125 (SBA-3125), and NmA-specific immunoglobulin G (IgG) concentrations.

151 on provided no advantage in sensitivity over immunoglobulin G (IgG) detection.

152 tags in a competitive immunoassay for rabbit immunoglobulin G (IgG) detection.

153 The delayed production of gB-specific immunoglobulin G (IgG) during primary HCMV infection is

154 We studied the prognostic relevance of serum immunoglobulin G (IgG) elevated above the upper limit of

155 ZIKV-NS1 immunoglobulin M (IgM) and immunoglobulin G (IgG) ELISAs combined can detect ZIKV i

156 by virus-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) enzyme-linked immunosorbent assay

157 he human repertoire of carbohydrate-specific immunoglobulin G (IgG) exhibits modular organization rel

158 Immunoglobulin G (IgG) Fc N-glycosylation affects antibo

159 Total immunoglobulin G (IgG) from individuals residing in mala

160 7BL/6 mice treated daily with purified serum immunoglobulin G (IgG) from patients with longstanding C

161 Adoptive transfer of purified immunoglobulin G (IgG) from the vaccinated animals with

162 study we demonstrate the potential value of Immunoglobulin G (IgG) glycosylation as a novel prognost

163 ollapsin response-mediator protein 5 (CRMP5) immunoglobulin G (IgG) has been associated with paraneop

164 N-linked glycans on immunoglobulin G (IgG) have been associated with pathoge

165 ted by detecting different concentrations of Immunoglobulin G (IgG) in both phosphate buffered saline

166 Calves with lower concentrations of immunoglobulin G (IgG) in their blood, have a greater ri

167 ad a combined diagnostic efficacy similar to immunoglobulin G (IgG) index and neurofilament light cha

168 (FcgammaRs) translate antigen recognition by immunoglobulin G (IgG) into various immune responses.

169 Immunoglobulin G (IgG) is a major effector molecule of t

170 were tested for anti-HPV-16 and anti-HPV-18 immunoglobulin G (IgG) levels by an L1 virus-like partic

171 Although anti-RBD immunoglobulin G (IgG) levels generally correlated with

172 , we tested plasma immunoglobulin A (IgA) or immunoglobulin G (IgG) levels specific for antigens in 9

173 amma receptors (FcgammaRs), the Fc domain of immunoglobulin G (IgG) mediates a wide spectrum of immun

174 ariate genome-wide association studies of 23 immunoglobulin G (IgG) N-glycosylation phenotypes.

175 We investigated the effect of FVIII-specific immunoglobulin G (IgG) on FVIII half-life in a cohort of

176 tion did not affect the immunoglobulin A and immunoglobulin G (IgG) plasmablast or memory B-cell resp

177 It is speculated that immunoglobulin G (IgG) plays a regulatory role in allerg

178 Myd88 repression leads to a decrease in immunoglobulin G (IgG) production against AAV2/1 and AAV

179 tion by naive B cells, which promoted B cell immunoglobulin G (IgG) production.

180 For higher immunoglobulin G (IgG) reactivity to EBV-viral capsid an

181 at mice globally deficient in the inhibitory immunoglobulin G (IgG) receptor FcgammaRIIB are protecte

182 e able to disseminate systemically to induce immunoglobulin G (IgG) response, which primarily targete

183 ecificity of plasma antibodies revealed that immunoglobulin G (IgG) responses against the glycoprotei

184 umococcal polysaccharides, often elicit weak immunoglobulin G (IgG) responses and are refractive to b

185 Heat maps for human immunoglobulin G (IgG) responses for each village and su

186 aluated the association between CMV-specific immunoglobulin G (IgG) responses in mothers at the time

187 A multiplex immunoassay to measure salivary immunoglobulin G (IgG) responses to 5 common norovirus g

188 Immunoglobulin G (IgG) responses to AM increased signifi

189 ed blood spot technique was used to evaluate immunoglobulin G (IgG) responses to both gSG6-P1 (Anophe

190 Here we studied naturally acquired immunoglobulin G (IgG) responses to GBS capsular polysac

191 Serum immunoglobulin G (IgG) responses were analyzed longitudi

192 Following infection, anti-norovirus salivary immunoglobulin G (IgG) rises steeply within 2 weeks and

193 .6%, respectively, showed anti-rubella virus immunoglobulin G (IgG) seroprotection.

194 ies depend greatly on the composition of the immunoglobulin G (IgG) structure, both in terms of prima

195 d 4 years off IS, and, at these time points, immunoglobulin G (IgG) subclass and C1q binding activity

196 Levels of immunoglobulin G (IgG) subclasses and C1q fixation in re

197 rmed BKV polymerase chain reaction (PCR) and immunoglobulin G (IgG) testing on pretransplant and seri

198 es) are natural T cell epitopes derived from immunoglobulin G (IgG) that were identified in 2008 and

199 Serum immunoglobulin G (IgG) titers to 28 pneumococcal protein

200 Transplacental transfer of maternal immunoglobulin G (IgG) to the fetus helps to protect aga

201 Thirty-four glycopeptides from human serum immunoglobulin G (IgG) tryptic digests were obviously ob

202 We cloned immunoglobulin G (IgG) variable domains from cryopreserv

203 The anti-CIP immunoglobulin G (IgG) was deposited on a silica optical

204 ree-dimensional (3D) ordered arrays of human immunoglobulin G (IgG) were fabricated using well-define

205 ds, (2) anti-B19V immunoglobulin M (IgM) and immunoglobulin G (IgG), (3) anti-VP1 IgG avidity, (4) an

206 .1%) were seroreactive for anti-glycoprotein immunoglobulin G (IgG), 89 (15.8%) were seroreactive for

207 haracterize the expression of membrane-bound immunoglobulin G (IgG), a fluorophore-labeled anti-mouse

208 -sectional analysis of serum anti-chlamydial immunoglobulin G (IgG), behavioral factors, and microbio

209 t pro-engulfment "eat me" signals, including immunoglobulin G (IgG), complement, and calreticulin, on

210 RV-specific immunoglobulin G (IgG), IgA, and neutralizing activity i

211 documenting reduced serum concentrations of immunoglobulin G (IgG), IgA, and usually IgM, together w

212 tigen-coated beads to quantify the levels of immunoglobulin G (IgG), IgM and IgA antibodies against f

213 es of these ZnO NWs were modified with mouse immunoglobulin G (IgG), infused through the second micro

214 rus, herpes simplex virus, and HCMV-specific immunoglobulin G (IgG), serum markers of inflammation, a

215 n this study, we developed novel recombinant immunoglobulin G (IgG)-binding luciferase-based signal a

216 omboembolism complicates disorders caused by immunoglobulin G (IgG)-containing immune complexes (ICs)

217 ia and prolonged COVID-19 symptoms, negative immunoglobulin G (IgG)-IgM SARS-CoV-2 serology, and posi

218 o linked antigen-binding fragments, to large immunoglobulin G (IgG)-like molecules with additional do

219 gocytosis and endocytosis, which internalize immunoglobulin G (IgG)-opsonized particles and polyvalen

220 mmunoassay (CLIA) with a high threshold, and immunoglobulin G (IgG)-specific CLIA with low threshold.

221 therapy were tested for HEV RNA and anti-HEV immunoglobulin G (IgG).

222 n-protein interfaces in the GB1 complex with immunoglobulin G (IgG).

223 ased class switched memory B cells and serum immunoglobulin G (IgG).

224 for regions contacting and interacting with immunoglobulin G (IgG).

225 for the sensitive and selective detection of immunoglobulin G (IgG).

226 ]) to investigate the persistence of measles immunoglobulin G (IgG).

227 streptavidin, barstar-dibarnase and Z domain-immunoglobulin G (IgG).

228 ses is blocked by autologous contemporaneous immunoglobulin G (IgG).

229 tibody receptor it encodes, FcgammaRIIA, for immunoglobulin G (IgG).

230 itated complex of GB1 with full length human immunoglobulin G (IgG).

231 onally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in v

232 dard markers of glomerular proteinuria (e.g. immunoglobulin G [IgG]), urinary nephrin excretion (podo

233 In this study, mAbs A-C of IgG1 and IgG4 (immunoglobulin G, IgG) isotypes with oxidized tryptophan

234 d interface for the attachment of monoclonal immunoglobulin G (IgGNS1) and to favor specific detectio

235 Here, we characterized polyclonal immunoglobulin Gs (IgGs) and Fabs from COVID-19 convales

236 latforms allow the reliable determination of immunoglobulins G (IgGs) from cows, sheeps, or goats.

237 Serum total free light chain, immunoglobulin G, immunoglobulin A, and immunoglobulin M

238 Kgp12, 17, and 18 were selected based on the immunoglobulin G immunoreactivity in the serum of patien

239 antibodies were positive in 15.7% cases and immunoglobulin G in 43.6% cases, respectively, when chec

240 ncreased immunoglobulin G index-the level of immunoglobulin G in the cerebrospinal fluid compared to

241 -neutralizing antibodies and anti-RSV fusion immunoglobulin G increased >=4-fold in 95% and 100% of v

242 nce of oligoclonal bands and/or an increased immunoglobulin G index-the level of immunoglobulin G in

243 International), immunoglobulin A (IgA) A and immunoglobulin G indirect immunofluorescence (IIF) on hu

244 -19) and expressed anti-spike protein trimer immunoglobulin G inhibited angiotensin-converting enzyme

245 ed determination of bovine casein and bovine immunoglobulin G is carried out in milk samples yielding

246 MG involved an immunoglobulin G isotype in all patients, with a predomi

247 iple myeloma was based on the presence of an immunoglobulin G lambda serum M protein (4,784 mg/dL) an

248 Inhibitory antibodies correlated with total immunoglobulin G levels to the EBA-175 binding domain (r

249 Nab titers and immunoglobulin G levels were correlated in donor plasma

250 ition was correlated with anti-spike protein immunoglobulin G levels, neutralizing titers in a pseudo

251 cted, nor were anti-tetanus and anti-measles immunoglobulin G levels.

252 in/blood ratio >300-fold higher than that of immunoglobulin G/liposomes.

253 Laboratory evaluation revealed immunoglobulin G MGUS in all 4 patients.

254 Anti-myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) antibodies are associated cli

255 The engineering of immunoglobulin-G molecules (IgGs) is of wide interest fo

256 Either total anti-HBc or anti-HBc immunoglobulin G (not immunoglobulin M) test should be u

257 lonal antibodies from HCV E2 peptide-binding immunoglobulin G-positive memory B cells.

258 Eighty-seven preterm infants of 69 CMV immunoglobulin G-positive mothers with birth weight <150

259 he anti-L-type voltage-gated calcium channel immunoglobulin G purified from patients with idiopathic

260 radish peroxidase, chicken avidin, and human immunoglobulin G, respectively.

261 Patients with LA mount a specific immunoglobulin G response against PG(Bb), which is signi

262 ng a novel serosurvey (VirScan) that detects immunoglobulin G responses to 206 viruses.

263 out jointly to find significant differential immunoglobulin G responses.

264 is commonly determined by measuring specific immunoglobulin G (RV IgG).

265 T-cell subsets and immunoglobulin G seropositivity for CMV, EBV, herpes-sim

266 We measured immunoglobulin G seroreactivity against 10 polyomaviruse

267 Analysis of purified immunoglobulin G showed functional growth inhibitory act

268 Among patients with residual disease, the immunoglobulin G signature was an independent, good prog

269 inked dimer fused to the Fc portion of mouse immunoglobulin G (sP-selectin-Fc).

270 Here, we studied isotypes, immunoglobulin G subclasses, and apparent affinities of

271 eptide microarray was designed to screen for immunoglobulin G targeting epitopes from all known cardi

272 Each immunized mouse had substantial immunoglobulin G targeting the challenge strains, indica

273 sis is challenging, as 9-month follow-up for immunoglobulin G testing is poor, quantitative polymeras

274 munosorbent assay (ELISA) to determine serum immunoglobulin G titers against Shigella LPS.

275 raised against these glycoconjugates showed Immunoglobulin G titers against the corresponding conjug

276 Higher anti-Vi immunoglobulin G titers were associated with less sheddi

277 Elevated serum immunoglobulin A and immunoglobulin G titers were associated with partial pro

278 Measles immunoglobulin G titers were measured by means of enzyme

279 Antimeasles serum immunoglobulin G titers were quantified using enzyme-lin

280 Antitetanus immunoglobulin G titers were similar between groups.

281 vant showed a rapid increase in anti-EBOV GP immunoglobulin G titers with peak titers observed on Day

282 tibodies showed positive immunoglobulin M or immunoglobulin G titers.

283 Specific antipneumococcal immunoglobulin G to 27 pneumococcal protein antigens and

284 Levels of immunoglobulin G to 35 recombinant CIDR domains were mea

285 vidin to biotinylated spheres and binding of immunoglobulin G to spheres functionalized with protein

286 longed allograft survival in comparison with immunoglobulin G-treated controls.

287 Positive anticardiolipin antibodies (>22 immunoglobulin G-type phospholipid units [GPLU]) were in

288 e adjustment, very high IgG aCL levels (>100 immunoglobulin G-type phospholipid units; relative risk

289 size of myofiber diameters, reduced myofiber immunoglobulin G uptake, and reduced muscle wasting at 3

290 ined continuum model of the antibody protein immunoglobulin G using fluctuating finite element analys

291 Serotype-specific immunoglobulin G was assayed before and 4 weeks postvacc

292 sma samples in which anti-EBOV nucleoprotein immunoglobulin G was detected.

293 n a second antibody, i.e. a HRP-labeled anti-immunoglobulin G, was deposited onto the biosensor.

294 associated changes have been recognized for immunoglobulin G, we sought to demonstrate the clinical

295 ntrations of serum GBS type III CPS-specific immunoglobulin G were 12.6 ug/mL (95% CI, 9.95 to 15.81)

296 Subgingival P. endodontalis levels and serum immunoglobulin G were associated with a higher EL score.

297 PT and anti-FHA (P < .001), but not anti-PRN immunoglobulin G, were observed among 69 wP-vaccinated i

298 assay (EIA) followed by immunoglobulin M and immunoglobulin G Western blots, performs well in late-st

299 croarray antibody capture assay for anti-HDV immunoglobulin G wherein recombinant HDV delta antigen i

300 model protein in human serum, that is, human immunoglobulin G, with the aim to demonstrate a virtuall